iTeos Therapeutics, Inc. (NASDAQ:ITOS) Sees Significant Increase in Short Interest

iTeos Therapeutics, Inc. (NASDAQ:ITOS) saw a large increase in short interest in the month of June. As of June 15th, there was short interest totalling 2,240,000 shares, an increase of 8.2% from the May 31st total of 2,070,000 shares. Based on an average daily volume of 435,500 shares, the days-to-cover ratio is currently 5.1 days. Currently, 8.1% of the shares of the stock are sold short.

Institutional Trading of iTeos Therapeutics

A number of hedge funds have recently bought and sold shares of ITOS. Gladius Capital Management LP raised its holdings in shares of iTeos Therapeutics by 48.7% during the fourth quarter. Gladius Capital Management LP now owns 3,131 shares of the company’s stock valued at $34,000 after acquiring an additional 1,026 shares during the period. PNC Financial Services Group Inc. raised its stake in iTeos Therapeutics by 131.5% during the 3rd quarter. PNC Financial Services Group Inc. now owns 2,287 shares of the company’s stock valued at $25,000 after purchasing an additional 1,299 shares during the period. Public Employees Retirement System of Ohio lifted its holdings in shares of iTeos Therapeutics by 4.9% in the first quarter. Public Employees Retirement System of Ohio now owns 39,003 shares of the company’s stock valued at $532,000 after purchasing an additional 1,817 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its position in shares of iTeos Therapeutics by 66.1% in the first quarter. China Universal Asset Management Co. Ltd. now owns 6,877 shares of the company’s stock worth $94,000 after buying an additional 2,737 shares during the period. Finally, Federated Hermes Inc. grew its holdings in shares of iTeos Therapeutics by 4,648.4% during the fourth quarter. Federated Hermes Inc. now owns 2,944 shares of the company’s stock valued at $32,000 after buying an additional 2,882 shares in the last quarter. 97.16% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several brokerages have recently weighed in on ITOS. Wedbush restated an “outperform” rating and issued a $21.00 price objective on shares of iTeos Therapeutics in a report on Monday, June 17th. HC Wainwright upped their price target on shares of iTeos Therapeutics from $44.00 to $46.00 and gave the company a “buy” rating in a report on Monday, May 13th.

iTeos Therapeutics Trading Down 3.8 %

Shares of NASDAQ:ITOS opened at $14.44 on Wednesday. The stock has a fifty day moving average of $15.27 and a 200-day moving average of $12.56. iTeos Therapeutics has a one year low of $8.20 and a one year high of $18.75.

iTeos Therapeutics (NASDAQ:ITOS) last announced its earnings results on Friday, May 10th. The company reported ($1.07) EPS for the quarter, missing the consensus estimate of ($1.02) by ($0.05). As a group, equities research analysts anticipate that iTeos Therapeutics will post -4.57 earnings per share for the current fiscal year.

iTeos Therapeutics Company Profile

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.